Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 87 от 100

Активно (без набиране) Фаза 2

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Small Cell Lung Cancer (SCLC)

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).

Начало: 26.02.2025 Край: 09.02.2029 Възраст: 18–99 г. Лечение

Argentina, Australia, Belgium +13 Amgen NCT06745323

Активно (без набиране) Фаза 2

A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations

Advanced or metastatic untreated EGFR mutation positive NSCLC

Trial status: Authorised • OS in patients treated with osimertinib first followed by dacomitinib and in patients treated with dacomitinib first followed by osimertinib • PFS at the time of study second-line therapy failure (PFS2) in patients treated with front-line osimertinib or dacomitinib; • PFS in patients treated with osimertinib first or dacomitinib first; • Response Rate (RR) with dacomitinib or osimertinib; • RR, PFS and OS with osimertinib followed by dacomitinib or with the opposite sequence in patients with u OS in patients treated with osimertinib first or dacomitinib first

Начало: 21.01.2025 Възраст: от 18 г.

Italy, Spain Fondazione Ricerca Traslazionale 2024-518223-29-00

Активно (без набиране) Фаза 2

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Solid Tumours

This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.

Начало: 30.12.2024 Край: 30.12.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +16 Boehringer Ingelheim NCT06619509

Активно (без набиране) Фаза 1

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

Solid Tumors Colorectal Cancer

The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).

Начало: 20.12.2024 Край: 30.09.2026 Възраст: от 18 г.

China Merck Healthcare KGaA, Darmstadt, Germany, an affiliate NCT06806046

Активно (без набиране) Фаза 1/2

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Neoplasms, Colorectal Solid Tumor Colon Cancer Rectal Cancer +1

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.

Начало: 13.12.2024 Край: 22.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Japan +4 GlaxoSmithKline NCT06710847

Активно (без набиране) Фаза 1/2

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.

Начало: 18.11.2024 Край: 28.08.2026 Възраст: от 18 г. Лечение

Australia, Brazil, Chile +3 Hoffmann-La Roche NCT06624059

Активно (без набиране) Фаза 1

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

Advanced or Metastatic MTAP-deleted Solid Tumors

This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.

Начало: 12.10.2024 Край: 30.04.2026 Възраст: от 18 г. Лечение

Australia, China, United States BeOne Medicines NCT06568614

Активно (без набиране) Фаза 1

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Advanced Solid Tumors

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

Начало: 10.10.2024 Край: 14.10.2027 Възраст: от 18 г. Лечение

Australia, Canada, United States Bristol-Myers Squibb NCT06544655

Активно (без набиране) Фаза 3

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.

Начало: 08.10.2024 Край: 01.06.2026 Възраст: 18–75 г.

China Shanghai Chia Tai Tianqing Pharmaceutical Technology De NCT06552520

Активно (без набиране) Фаза 3

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Начало: 09.09.2024 Край: 29.05.2028 Възраст: 18–99 г.

Argentina, Austria, Brazil +21 Amgen NCT06311721

Активно (без набиране)

Physical Activity Centers Empowerment

Colorectal Neoplasms

This research study tests the feasibility of the Physical Activity Centers Empowerment (PACE) physical activity intervention for African American individuals diagnosed with colorectal cancer. Feasibility will be measured as intervention reach, effectiveness, adoption, implementation, and maintenance. Seventy-two subjects will be recruited to conduct a pilot two-group, randomized repeated measures study.

Начало: 14.08.2024 Край: 01.06.2026 Възраст: от 18 г.

United States UNC Lineberger Comprehensive Cancer Center NCT06411756

Активно (без набиране) Фаза 3

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBCL will be enrolled in approximately 165 sites across the world. Participants in arm A will receive subcutaneous (SC) injections of epcoritamab plus oral lenalidomide capsules (E-Len) for up to 12 cycles (each cycle is 28 days). Participants in arm B will receive intravenously (IV) infused R-GemOx for up to 4 cycles (each cycle is 28 days). Participants in arm C will receive SC injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Начало: 13.08.2024 Край: 01.03.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Genmab NCT06508658

Активно (без набиране) Фаза 2

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

Indolent B-Cell Non-Hodgkin Lymphoma

Trial status: Authorised Evaluation of PK parameters for BI-1206 during the BI-1206 treatment period., Evaluation of ADA response to BI 1206., Measurement of B cell depletion., Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014). Other endpoints will include time to objective response, duration of response, PFS, and OS., CD32b protein expression levels., Expression levels of CD32b and/or other immunological markers. • Documenting AEs and SAEs (graded according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events CTCAE, and determining causality in relation to BI 1206, rituximab or acalabrutinib.. Causality of AEs/SAEs will be assessed by the Investigator., Phase 1: • Determining the MTD of BI-1206, with no more than 1 of up to 6 subjects at the same dose level experiencing DLT during the 28-day treatment period on induction therapy (i.e., by Day 29/Week 5). If pharmacokinetic (PK) and pharmacodynamic (PD) data suggest an optimal therapeutic dose, the escalation may be halted by the Cohort Review Committee (CRC) prior to reaching the MTD, and the RP2D will be based off the PK, PD, safety tolerability and efficacy data., Phase 2a, BI-1206 in Combination with Rituximab and Acalabrutinib: The recommended dose will be derived from totality of PK, PD, clinical response, safety, and tolerability observed.

Начало: 12.08.2024 Възраст: от 18 г.

Germany, Spain BioInvent International AB 2024-512972-36-00

Активно (без набиране) Фаза 2

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Advanced Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy. The names of the study drugs involved in this study are: * AGEN1423 * Botensilimab Participants will receive study treatment for about 2 years and will be followed for 1 year after.

Начало: 08.08.2024 Край: 01.04.2027 Възраст: от 18 г.

United States Bruno Bockorny NCT05632328

Активно (без набиране)

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

Hepatocellular Carcinoma

This study is a single-arm, open-label trial to clarify the safety and efficacy of the combined treatment of lenvatinib and VIC-1911 in patients with advanced liver cancer.

Начало: 01.08.2024 Край: 31.07.2026 Възраст: 18–75 г.

China RenJi Hospital NCT06519721

Активно (без набиране) Фаза 1

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)

Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations

Trial status: Authorised

Начало: 11.07.2024 Възраст: от 18 г.

France, Italy, Netherlands +1 Arrivent Biopharma Inc. 2023-508349-42-00

Активно (без набиране) Фаза 3

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Extensive-Stage Small-Cell Lung Cancer Small-Cell Lung Cancer

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Начало: 05.06.2024 Край: 30.09.2028 Възраст: 18–99 г. Лечение

Argentina, Australia, Belgium +23 Amgen NCT06211036

Активно (без набиране) Фаза 1

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Hodgkin Disease Lymphoma, T-Cell, Peripheral Lymphoma, Large B-Cell, Diffuse Lymphoma, Large-Cell, Anaplastic

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.

Начало: 28.05.2024 Край: 13.04.2026 Възраст: от 18 г.

Denmark, France, Italy +3 Seagen, a wholly owned subsidiary of Pfizer NCT06254495

Активно (без набиране) Фаза 1

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

AML/MDS CD33 Expressing Hematological Malignancies FLT3 Expressing Hematological Malignancies

This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.

Начало: 22.04.2024 Край: 01.08.2040 Възраст: 18–74 г. Лечение

Australia, United States Senti Biosciences NCT06325748

Активно (без набиране) Фаза 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Head and Neck Squamous Cell Carcinoma (HNSCC)

Trial status: Authorised 1. PFS defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) as assessed by the investigator, or death from any cause, whichever occurs first, 2. ORR defined as the percentage of participants who have a complete response (CR) or a partial response (PR) per RECIST v1.1 as assessed by the investigator, 3. DCR defined as the percentage of participants who have achieved a CR, PR, or stable disease (SD) for at least 8 weeks per RECIST v1.1 (as assessed by the investigator), 4. Duration of response (DOR), defined for participants who have a confirmed CR or PR as the time from the date of first documented response (which is subsequently confirmed) per RECIST v1.1, as assessed by the investigator, until date of documented PD or death due to any cause, whichever occurs first, 5. Incidence and severity of adverse events (AEs); Incidence and severity of laboratory abnormalities, 6. Concentrations of ficlatuzumab in serum samples, 7. The presence of antidrug antibodies (ADA) to ficlatuzumab based on seroconversion status, and the evaluation of the potential impact of ADA on PK, efficacy, and safety • The presence of neutralizing antibodies, when ADA is positive, and the evaluation of the potential interference of ADA on ficlatuzumab-HGF binding, 8. Change from baseline in the European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-Head and Neck Module 35 (H&N35) • Time to clinically meaningful deterioration in scores on the EORTC H&N35 • Change from baseline in overall health status per the EuroQol-5 dimensions-3 level (EQ-5D-3L) Overall survival (OS), defined as the time from the date of randomization to the date of death for any cause

Начало: 16.04.2024 Възраст: от 18 г.

Belgium, Bulgaria, Czech Republic +8 Aveo Pharmaceuticals Inc. 2023-505606-42-00

1 … 85 86 87 88 89 … 100